Intercept Pharmaceuticals (NASDAQ:ICPT) was reiterated an Outperform and share price target held at $239 by analysts at Wedbush on Monday.
Interim results from Intercept's competitor suggest reduced competition risk, said Wedbush.
“Recently, Intercept's competitor Tobira (TBRA; not covered) announced interim results from the company's 52-week Phase 2b trial of cenicriviroc (CVC) in patients with NASH. The company reported that the trial did not meet its primary endpoint of demonstrating a two-point reduction in NAFLD activity score (NAS) nor achieved a secondary endpoint of complete resolution of steatohepatitis,” the analyst said in a note.
Wedbush said the Phase 2b results from competitor Tobira reinforced the analysts’ view that Intercept’s OCA is “not only first-in-class but also best-in-class.”
Intercept shares were up 0.03% at $158.25 on Monday.
Meanwhile, Cameco Corporation (NYSE:CCJ, TSE:CCO) was recommended a Buy with a share price target of C$22.20 by Dundee Capital Markets on Monday.
“We still see value as Cameco trades at a heavy discount to historic levels, approaching a 12-year low. High priced contracts help insulate revenue from low U3O8 prices; we expect a 54% premium to average Q2/16 spot price; or 70% above current spot as it fell last week to US$25.25/lb; lowest since 2005,” said Dundee.
Cameco is one of the world's largest uranium producers at 14% of global production. It has around 1 billion pounds of U3O8 resources.
However, Cameco shares came off 1% to $10.24 on Monday in New York and was down 0.7% at C$13.50 in Toronto.